ARTICLE | Clinical News
ISIS 2302 antisense inhibitor of intercellular adhesion molecule 1: Phase IIa trial
December 9, 1996 8:00 AM UTC
Isis Pharmaceuticals (ISIP), Carlsbad, Calif. Product: ISIS 2302 antisense inhibitor of intercellular adhesion molecule 1 ( ICAM-1) Indication: Crohn's disease Status: ISIP completed the first Phase ...